Instinct Bio Technical Company Holdings Inc., a company incorporated in the Cayman Islands on May 22, 2025. The company is committed to the development, production and sale of skin care and health products based on regenerative stem cells. With advanced biotechnology and proprietary formulation technology, the company focuses on the development of stem cell-based cosmetics designed to promote skin regeneration, enhance skin vitality and have anti-aging effects. The company's product portfolio includes serums, creams, lotions and masks, all of which are developed with scientific innovation and superior efficacy as the core research and development concepts. The company operates in a vertically integrated model, covering product innovation, manufacturing and strategic distribution channels, including partnerships, retail distribution and e-commerce platforms. 

Instinct Bio has secured a 213 m² premises in Jakarta for its first GENRÊVER CLINIC site, with construction underway. The company plans to open by year-end, and has finalized preliminary subscription pricing tiers for the clinic. Instinct Bio and Invitrx have identified an initial GENRÊVER-branded cosmetic product line-up for potential manufacture in the US, while the company and Parva have identified two initial cosmetic product candidates for the Indonesian market. Production is targeted to commence within 2026, subject to regulatory compliance and manufacturing readiness.

Instinct Bio

Instinct Bio Updates on Indonesian Growth Platform and Product Dev Initiatives

Instinct Bio has secured a 213 m² premises in Jakarta for its GENRÊVER CLINIC site, with interior construction underway and a target opening by end-December 2026. The company has finalized subscription pricing tiers for the clinic and identified initial GENRÊVER-branded cosmetic products for potential US manufacture in 2026. It has also identified two cosmetic product candidates for the Indonesian market under the GENRÊVER and HAKUA brands, with production targeted for 2026. Instinct Bio is a biotechnology company focused on regenerative medicine, wellness-related technologies, and aesthetic treatments.

Instinct Bio Updates GENRÊVER CLINIC, Product Dev Collaborations

Instinct Bio provides operational update on Indonesia growth platform, GENRÊVER CLINIC, and product development initiatives. The company has secured a 213 m² premises in Jakarta for its first GENRÊVER CLINIC site and has finalized preliminary subscription pricing tiers. Instinct Bio and Invitrx Therapeutics have identified an initial GENRÊVER-branded cosmetic product line-up for potential manufacture in the US, while Instinct Bio and Parva Candela have identified two initial cosmetic product candidates for the Indonesian market. Production is targeted to commence within 2026, subject to regulatory compliance and manufacturing readiness.

Instinct Bio Secures Jakarta Clinic Site, Targets December Opening

Instinct Bio (BIOT) shares rose 11.67% in pre-market trading after the publication of a real-world study in Frontiers in Gastroenterology evaluating its diagnostic products, IBS-Smart and Trio-Smart. The study, funded by the company, reports significant cost savings and reduced use of invasive procedures for IBS patients, providing a positive economic narrative for the company's technology.

Instinct Bio (BIOT) rises 11.67% premarket after publication of real-world study on diagnostic products

The 15-minute chart for Instinct Bio has triggered a MACD Death Cross and a Bearish Marubozu pattern at 08/13/2026 14:30. This indicates that the stock price may continue to decline, as sellers dominate the market and bearish momentum is expected to persist.On August 13, 2026, at 14:30, the 15-minute chart for Instinct Bio Technical Company Holdings Inc. (NASDAQ: BIOT) displayed a MACD Death Cross and a Bearish Marubozu pattern, signaling potential downward momentum in the stock price. These technical indicators suggest that sellers are currently dominating the market, with <a href="https://www.investopedia.com/terms/d/deathcross.asp">bearish sentiment likely to persist</a> in the near term.The MACD Death Cross occurs when the short-term moving average crosses below the long-term moving average, a pattern historically associated with bearish trends. Meanwhile, the Bearish Marubozu candlestick pattern, characterized by a long lower shadow and no upper shadow, indicates <a href="https://www.investopedia.com/terms/d/deathcross.asp">strong selling pressure</a> and a lack of buyer participation during the period.Instinct Bio, which operates in the regenerative medicine and stem cell technology sector, has been the subject of several recent developments, including strategic partnerships and expansion plans in Asia. However, the current technical indicators suggest caution for investors, as they reflect <a href="https://www.investing.com/equities/relativity-acquisition-a">a shift in market sentiment</a> toward the downside.Historically, the death cross has not always led to prolonged bear markets, and in some cases, it has been followed by short-term rebounds. Nevertheless, the pattern is widely regarded as a bearish signal, particularly when it occurs <a href="https://www.investopedia.com/terms/d/deathcross.asp">after a period of price weakness</a>. Investors are advised to monitor the stock closely and consider <a href="https://www.investopedia.com/terms/d/deathcross.asp">broader market conditions, fundamentals</a>, and volume trends before making trading decisions.As of the close of the referenced time period, BIOT was trading at $0.38, with a 52-week range spanning from $0.38 to $50.00. The stock’s recent volatility underscores the importance of <a href="https://www.investing.com/equities/relativity-acquisition-a">a well-defined risk management strategy</a> for those holding or considering a position in the stock.

BIOT News